Compare GE Vernova Inc (GEV) vs Oscar Health Inc (OSCR) Price & Performance

GE Vernova (GEV) trades at $1,042.98, up 5.26% over 24 hours, reflecting strong momentum near its pivot point of $1,017. The stock exhibits bullish technical signals with moving averages supporting the uptrend. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $17.44 significantly exceeding expectations, though Q2 2026 saw a miss. Revenue growth is solid, projected to rise from $38.07B in 2025 to $41.4B in 2026, while net income margin expanded to 23.04%. The company benefits from a massive $176 billion backlog, positioning it to capitalize on AI-driven power demand.

Outlook remains positive given GEV's strategic role in addressing AI infrastructure bottlenecks, but high valuations (P/E 29.01, EV/EBITDA 86.33) pose risks if execution falters. Analyst consensus is strongly bullish with a $1,270 price target, though investors should monitor quarterly execution against lofty expectations and competitive pressures in the energy sector.

Oscar Health (OSCR) trades at $29.11, up 5.2% with strong recent earnings momentum, beating estimates in Q1 and Q2 2026. The stock shows bearish technical signals but benefits from record profitability and raised 2026 guidance. Revenue surged 70% to $4.9 billion in H1 2026, with net income turning positive at $551 million versus a 2025 loss. Valuation remains attractive with P/S of 0.53, suggesting potential undervaluation versus sector peers.

Outlook is positive given membership growth and cost discipline, but risks include medical cost volatility and competitive pressures. Analyst consensus price target of $32.50 implies 12% upside, though technical resistance near $30 may limit near-term gains. Execution on guidance and sustained margin expansion are key catalysts.